Back to News
May 8, 2026 12:30 PM

Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) are down on Friday as the company announced initial clinical data regarding its AlloNK (AB-101) in combination with rituximab for autoimmune diseases and a $300 million private placement.

Artiva (ARTV) AlloNK Clinical Data

Artiva Biotherapeutics recently reported a 71% ACR50 response in refractory rheumatoid arthritis patients from its Phase 2a trial, highlighting the potential of its AlloNK therapy.

Patients with only 12 weeks of follow-up demonstrated early improvements across disease activity measures consistent with those observed in patients with six or more months of follow-up.

Following a recent FDA interaction, ...